

B 101

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
14 June 2001 (14.06.2001)

PCT

(10) International Publication Number  
WO 01/41581 A1

- (51) International Patent Classification<sup>7</sup>: A23D 9/00, Marie-Rose, Louisa, Dominique [BE/BE]; Struweel-  
A23L 1/305, A23J 3/34 gaard 9, B-1700 Dilbeek (BE).
- (21) International Application Number: PCT/NL00/00913 (74) Agent: JORRITSMA, Ruurd; Nederlandsch Octrooi-  
bureau, Scheveningseweg 82, P.O. Box 29720, NL-2502 LS  
The Hague (NL).
- (22) International Filing Date: 13 December 2000 (13.12.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 99204287.9 13 December 1999 (13.12.1999) EP
- (71) Applicant (for all designated States except US): N.V. NU-  
TRICIA [NL/NL]; P.O. Box 1, NL-2700 MA Zoetermeer  
(NL).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): BINDELS, Jacob,  
Geert [NL/NL]; Ligusterpark 2, NL-2724 HJ Zoetermeer  
(NL). VAN BAALEN, Antonie [NL/NL]; Bredasingel  
131, NL-6843 RC Arnhem (NL). HAGEMAN, Robert,  
Johan, Joseph [NL/NL]; Weidezoo 52, NL-2742 EV  
Waddinxveen (NL). HUYBERS, Peti [NL/NL]; Laven-  
del 182, NL-5432 DK Cuyk (NL). DUMON, Liliane,
- (81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,  
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,  
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,  
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:  
— With international search report.
- For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: INFANT FORMULA WITH IMPROVED PROTEIN CONTENT

(57) Abstract: An improved infant formula resulting in reduced constipation, abdominal discomfort and gastrointestinal problems, comprises at least one protein component having a phosphorus content of less than 0.75 g P/100 g protein, and at least one lipid component that can be easily digested by an infant. Preferably, it further comprises at least one prebiotic component, and at least one viscosity-improving component. The protein fraction of the formula is preferably a hydrolysate prepared by hydrolysing a protein starting material, especially a whey protein with a combination of at least one endo- and at least one exoprotease.

WO 01/41581 A1

WO 01/41581

PCT/NL00/00913

**Infant formula with improved protein content**

The present invention relates to an improved infant formula containing at least an easily digestible lipid component and an improved protein component.

5 In infants, in particular in infants of less than 6 months old, the digestive system has to develop and adapt to food. Because of this, for the first months of their lives, infants are usually fed specialised infant formulas.

Usually, such infant formulas are well tolerated. However, in a limited number of cases, conventional formulas may lead to minor problems, in a particular with respect to the  
10 processes that occur in the gastrointestinal tract.

More in particular, in the research leading up to the present invention, it was acknowledged by the inventors that conventional formulas may lead to undesired disturbances in the natural gut flora and/or to an unnatural gut flora. Also, it was acknowledged that conventional infant formulas may provide the wrong type and/or the  
15 wrong amounts of substrate; and/or may have the wrong composition of diet components.

Such defects in conventional formulas may lead to undesired processes in the gastrointestinal tract and/or to an undesired disturbance of the natural processes. In turn, this may lead to symptoms such as:

- an undesirable constitution of faeces (e.g. diarrhoea, constipation or unnatural colour  
20 tone);
- high local gas production, which may result in cramps in the infant gut and/or to bloating and delayed stomach emptying;
- a decreased bioavailability of divalent cations;
- undesired levels of aggressive agents in the faeces, in particular agents that can irritate  
25 and/or damage the epithelial cells (such as those of the lining of the gastrointestinal tract and/or the skin) including but not limited to proteases.

As a result, infants which are fed conventional formulas may suffer from reduced appetite and/or regurgitation of food (often in case of disturbances in the gut). Also, disturbances in the natural process of stomach emptying and an irregular consumption  
30 pattern may occur, which may cause hunger, as a result of which infants may consume large volumes of formula too hastily, which in turn may lead to excessive aerophagia and/or regurgitation.

Also, as a result of the problems, causes and/or factors indicated above, infants which are fed conventional formulas may suffer from an impaired immune function which

WO 01/41581

2

PCT/NL00/00913

may become evident in rapid development of a rash on the skin of the bottom; under-nourishment (impaired growth), malfunctioning (colic) and even damage to the gut (intolerances to food components).

Thus, there is a need for an infant formula that has improved characteristics with respect to the prevention and/or alleviation of one or more, and preferably all, of the above-mentioned problems. The present invention provides such an infant formula.

In this respect, it is of importance that the formula of the invention is capable of preventing, alleviating and/or reducing all of the above-mentioned problems simultaneously. This is because, in particular for a parent, it may be difficult to establish the specific cause of the problem(s). Thus, by using an infant formula of the invention that can prevent and/or alleviates all of these problems simultaneously, parents may be assured that by the use of the infant formula of the invention, all such problems can be reduced, irrespective of the cause thereof, and without having to switch from one formula to another until one has found an infant formula that reduces the presently occurring problem(s) without causing any of the other problem(s) mentioned above.

Usually, when one or more of the above problems occur/persist, a parent will usually switch to another formula or - if that does not help - consult a paediatrician. However, of all infant formulas currently on the market, none has characteristics that can prevent or alleviate all of the above-mentioned problems simultaneously. Thus, the switching to another formula may not reduce the problem and/or may lead to one or more of the other problems mentioned above. Also, the infant may have problems getting used to (the taste of) the new formula, which may lead to a reduction in appetite. The latter may in particular be a problem when - because of the above-mentioned problems - the formula is or has to be changed several times.

In the research leading up to the present invention, it was acknowledged by the inventors that some of the major causes of the disturbance(s) of the processes in the gastrointestinal tract as may occur with conventional infant formulas include:

- the fact that, in the triglycerides present in the (lipid component of) conventional infant formulas, undesirably high amounts of palmitic acid, myristic acid, and/or stearic acid are present in the Sn1- or Sn3-position of glycerol;
- the fact that conventional infant formulas contain undesirably high amounts of divalent cations, and in particular undesirably high amounts of calcium ions. In particular, this is a problem when at the same time, there are high amounts of palmitic acid, myristic acid, and/or stearic acid are present in the Sn1- or Sn3- position of the triglycerides present,

WO 01/41581

3

PCT/NL00/00913

i.e. as mentioned above;

- the fact that conventional infant formulas contain insufficient amounts of suitable substrates for micro-organisms, i.e. for the naturally occurring intestinal flora.

Thus, according to the invention, these above-mentioned problems are solved by the following measures, which result in an infant formula according to the claims.

Firstly, an infant formula is provided that - in the lipid/triglyceride components present therein - does not contain high amounts of these saturated fatty acids in the Sn1- or Sn3-position of glycerol, and in particular does not contain high amounts of palmitic acid in the Sn1- or Sn3- position. This can be achieved by using, in the preparation of an infant formula of the invention, a lipid component that:

- contains lipids that have relatively large amounts of C14:0, C16:0 and C18:0 in the Sn2 position of glycerol, such as specific phospholipids or triglycerides of animal, microbial or plant origin, in which the triglycerides have been subjected to enzymatic or other re-esterification such that the palmitic acid residues are for a large part present in the 2-position;
- contains a relatively small amount of fatty acids of the type C14:0, C16:0 and C18:0, especially C16:0.

Secondly, an infant formula is provided that contains a relatively low amount of divalent cations, especially of magnesium and/or calcium, and in particular a low amount of calcium ions, e.g. in the amounts mentioned below.

In conjunction with/in addition to (or even instead of) these low amounts of calcium, according to the invention the bio-availability of said cations may be improved; for instance by assuring that, at pH 6-7 (e.g. under the conditions prevalent in the duodenum), most of the calcium salts provided by the formula of the invention are in the form of water soluble salts (e.g. no or only low amounts of basic phosphate and/or citrate salts).

Also, as mentioned below, preferably the amount of phosphorus in the infant formula should be as low as possible, e.g. as defined below. Inter alia, according to the invention, this is achieved by using proteins, and in particular protein hydrolysates, with a low phosphorus content, as further described below.

In this respect, the use of a protein hydrolysate also ensures that the protein components present in the infant formula of the invention do not sensitise the infants. The use of the hydrolysates also ensures that the protein components can be easily absorbed from the gastrointestinal tract, and thus do not interfere (too much) with the processes occurring in the intestines (and in particular in the colon).

Also, as will be further described below, the use of a protein hydrolysate - in conjunction with the favourable osmotic value provided by the formula of the invention - will promote the natural processes of stomach emptying, which will prevent and/or reduce regurgitation.

5 Thirdly, an infant formula is provided that contains a sufficient amount of substrate for creation and maintenance of a beneficial flora in the whole gut, especially in the colon. This ensures a uniform production of gas and beneficial substances such as short chain fatty acids, and also prevents the release of excessive amounts of aggressive agents. In human breast milk lactose and oligosaccharides provide this substrate. In conventional infant  
10 formula lactose is the only source. It has been found that, most preferably, a source of oligosaccharides is present in the general purpose formula according to the invention, e.g. in addition to or instead of lactose, the latter especially for those infants that are (partly) intolerant to lactose.

Thus, the present invention provides an infant formula that comprises any  
15 combination of two or more, preferably of three or more, and most preferably all, of the following components:

- a) at least one protein component (here below also referred to as "*component A*");
- b) at least one lipid component that can be easily digested by an infant ("*component B*");
- c) at least one prebiotic component ("*component C*");

20 at least one viscosity improving component ("*component D*");

and that optionally further contains any component of infant formula known per se, including but not limited to those described below (here below referred to as "*further components*"); and in which the components A to D and the one or more further components are preferably as described below.

25 The protein component may comprise whole proteins and/or a protein hydrolysate, or a mixture thereof, and is most preferably low in phosphorus, e.g. a phosphorus content of less than 0.75 g/100g protein. Also, when whole proteins are present, they are most preferably such that they are easily digested by the infant, e.g. as described below.

30 Preferably, the entire infant formula of the invention has a phosphorus content as defined below.

As the source of the protein component preferably mammalian milk, e.g. bovine milk, goats milk or horses milk, is used

In particular, an infant formula of the invention may be characterised in that:  
the protein component a) is a protein hydrolysate, obtained by hydrolysing a starting

material comprising a milk protein, a mixture of milk proteins, and/or a milk protein preparation with a combination of at least one endo- and at least one exoproteinase; and may further be characterised in that:

the at least one lipid component b) comprises at least one fatty acid triglyceride and/or a mixture of fatty acid triglycerides, in which:

- palmitic acid residues make up more than 10 %, up to e.g 30% or higher, preferably 16 - 24 %, of all fatty acid residues present in the triglycerides; and in which,
- triglycerides in which the palmitate residue is in the Sn1- or Sn3-position make up no more than 16 %, more preferably no more than 13, and most preferably no more than 10.7 %, of all triglycerides present.

Most preferably, an infant formula of the invention - e.g. containing any two or more, and preferably three or more of the components A to D as mentioned above - is further characterised in that said formula for the most part, and preferably essentially only, contains calcium ions that have a high biological availability, e.g. as described below.

Preferably, the infant formula of the invention is the form of powder, that prior to use is dissolved by the end-user (i.e. the parent) in warm or cold, and preferably luke-warm, water or another suitable liquid carrier, e.g. in an amount of 9 – 17 g powder per 100 ml water. Both said powder, optionally packaged in a suitable container such as a tin, a box, a bag, a flask or a sachet, as well as the ready-to-use formula obtained by dissolving the powder, form aspects of the invention.

Preferably, the infant formula of the invention contains at least one component A and/or at least one component B in the amount(s) indicated below, i.e. in combination with at least one, preferably at least two, and most preferably all three of the other components [B to D] or [A, C and/or D], respectively; and optionally one or more further components.

More preferably, the infant formula of the invention contains a combination of components A + B + C; and optionally one or more further components.

Generally, in a preferred formula containing at least components A and B, the relative amounts of the above components will be generally as follows:

- Component A: 6.4 to 16.0 wt.%
- Component B: 18 to 29 wt.%
- Component C: 0 to 15 wt.%
- Component D: 0 to 15 wt.%
- Further components: 0 to 60 wt.%

to a total of 100 wt.% of the final formula (e.g. of the powdered formula).

WO 01/41581

6

PCT/NL00/00913

In a more preferred infant formula containing at least components A, B and C, the relative amounts of the above components will generally be as follows:

- Component A: 6.4 to 16.0 wt.%
- Component B: 18 to 29 wt.%
- 5 - Component C: 3.0 to 15 wt.%
- Component D: 0 to 15 wt.%
- Further components: 0 to 60 wt.%

to a total of 100 wt.% of the final formula.

10 In the infant formula containing all four components A, B, C and D, the relative amounts of the above components will generally be as follows:

- Component A: 6.4 to 16.0 wt.%
- Component B: 18 to 29 wt.%
- Component C: 3.0 to 15 wt.%
- Component D: 1.5 to 15 wt.%
- 15 - Further components: 0 to 60 wt.%

to a total of 100 wt.% of the final formula.

It is envisaged that several infant formulas of the invention may be developed, e.g. with different properties, a range of tastes, and/or for different ages of the infant.

20 It is further envisaged that such formulas may differ as to which of the components A to D and further components are present; which particular compounds/ingredients are used as components A to D and/or as further components; and/or in the (relative) amounts of thereof.

25 In particular, it is envisaged that there may be developed infant formulas of the invention intended for infants less than 6 months old, as well as infant formulas of the invention intended for infants of more than 4 months old, and in particular more than 6 months old. These will be further discussed below.

30 The proteins that are preferably used as component A have a relatively low phosphorus content. 100 g protein must provide less than 0.75 g phosphorus, preferably less than 0.72 g and even more preferably less than 0.69 g. Whey proteins, dephosphorylated casein or soy protein and mixtures thereof, as well as specific protein fractions from caseins - such as those from which part of, and preferably most,  $\alpha$ -caseins have been removed - are suitable sources

The protein hydrolysates that are preferably used as component A form a further and separate aspect of the invention, as does the method for preparing said preferred

hydrolysates. It is envisaged that these hydrolysates may find other applications besides their use in the formulas of the invention, as further discussed below.

The preferred protein hydrolysates A - when used in the amounts indicated below - will generally provide the final formula of the invention with one or more - and preferably

all - of the following properties:

- a peptide profile - i.e. for the proteins derived from the hydrolysate - as described below;
- a good taste, and in particular a taste that is not bitter, which is an extremely important characteristic for infant formulas in general, and for the infant formulas of the invention in particular;
- a content of free amino acids of less than 10 g, and preferably less than 7 g per 100 g protein equivalent (calculated by multiplying the Kjeldahl nitrogen by 6.25; in which the amount of nitrogen that is measured is determined by the amount of proteins, peptides, amino acids and other nitrogen sources in the product), based upon the final formula;
- an osmolality of less than 270 mOsmol/l, preferably less than 240 mOsmol/l, most preferably less than 230 mOsmol/l. Inter alia, an osmotic value in this range will assure that the infant formula of the invention will not disturb (e.g. inhibit) the natural process of stomach emptying in the infant;
- low sensibilisation, for instance as determined by the tests described by J.J. Pahud and K. Swartz in *Proc. of the Tropical Conference, Virginia 1985*, AOAC, 264-271; and/or Piacentini et al., *Allergy* 1994, 48, 361-364 or any other suitable test.

In the tests described by Pahud and Swartz or by Piacentini, the infant formula of the invention preferably shows a degree of sensitisation properties that is preferably essentially zero .

Furthermore, according to one preferred aspect, when the infant formula of the invention contains the preferred lipid component B described below, the formula of the invention may have a reduced overall fat content, compared to conventional infant formulas. According to this aspect of the invention, the infant formula of the invention may have an overall fat content (expressed as total lipid content) of less than 46 wt.%; as compared to 48 wt.% or more for conventional infant formulas.

In the formula of the invention, Medium Chain Triglycerides (MCTs) can be used to replace partially triglycerides containing palmitic acid residues. If so, it is preferred that such MCTs are used in an amount of less than 20 wt.% of the total lipid component B.

Also, as further discussed below, when the infant formula of the invention contains the preferred lipid component B, an infant formula of the invention may not require amounts



of calcium to be present, that are as high as the calcium contents required in conventional formulas.

In particular, according to this aspect of the invention, an infant formula of the invention for infants of less than 6 months old may have a calcium content (expressed as mg of calcium per 100 kcal of energy content of the formula) of less than 80 mg/100kcal, and preferably less than 77 mg/100 kcal (e.g. 70 mg/100kcal); as compared to 82-120 mg/100 kcal for conventional infant formulas. In order to provide sufficient calcium to the infant, the concentration of calcium should be above 50 mg/100kcal.

An infant formula of the invention for infants of more than 6 months old may have a calcium content (expressed as mg of calcium per 100 kcal of energy content of the formula) of less than 122 mg/100kcal, and preferably less than 116 mg/100 kcal (for example 110 mg/100kcal); as compared to 125 mg /100kcal or more for conventional infant formulas.

Such a reduced calcium content may have certain advantages, such as decreased formation of fatty acid soaps in the gut and more natural exposure of calcium ions to the enterocytes in the duodenum and other parts of the gut and to the gut flora. In addition it was found that less technological problems related to sedimentation occurred, e.g. during the preparation of the formula.

Calcium is preferably added to the infant formula of the invention as soluble salt(s), such as the hydroxide or chloride salts. Tribasic phosphate and citrate salts are insoluble. In addition, it is aimed to prevent that during manufacture insoluble calcium salts are formed, such as phosphates and/or citrates.

Also, as in infant formula the amount of phosphorus present generally depends upon the calcium content, in that in conventional infant formula the ratio of calcium-to-phosphorus is generally between 1.5 and 2.0, and usually about 2, the infant formula of the invention may also have a reduced phosphorus content.

For instance, based upon the calcium contents mentioned above and a general calcium-to-phosphorus ratio about 2, an infant formula of the invention for infants of less than 6 months old may have a phosphorus content (expressed as mg of phosphorus per 100 kcal of energy content of the formula) of less than 40 mg/100kcal, and preferably less than 38,5 mg/100 kcal (e.g. 38 mg/100kcal); whereas an infant formula of the invention for infants of more than 6 months old may have a phosphorus content (expressed as mg of phosphorus per 100 kcal of energy content of the formula) of less than 61 mg/100kcal, and preferably less than 58 mg/100 kcal (e.g. 38 mg/100kcal).

Such a reduced phosphorus content may have certain advantages, such as less

sedimentation during manufacture and increased bioavailability of divalent cations.

When besides the phosphorus provided by proteins and/or phospholipids extra phosphorus has to be added, this is especially done by adding monobasic phosphates, preferably from sodium and/or potassium.

5 Alternatively, when an infant formula of the invention has a reduced calcium content as described above, the formula of the invention may be prepared at reduced calcium-to-phosphorus ratio of between 1.4 and 2. Such a reduced calcium-to-phosphorus ratio may also have certain advantages, such as to compensate for certain properties of the water that is used by the final user to prepare the formula, e.g. by dissolving the powdered formula of  
10 the invention.

Also, when one or more prebiotic components C are present in the infant formula of the invention, the content thereof is preferably at least 0.3 g/100 ml of the total formula, more preferably at least 0.6 g/100 ml of the total formula. When the formula is given to infants in the usual amounts - e.g. of at least about 200 ml per day (mainly depending upon  
15 the age of the infant) as one or more, and preferably 4 or more, feedings per day - this will correspond to a total daily dose of prebiotic components of at least 1.8 g/day (again mainly depending upon the age of the infant).

Furthermore, when one or more viscosity improving components D are present, the viscosity of the final formula is preferably between 20 and 100 cps, more preferably  
20 between 40 and 80 cps; as measured in a Brookfield viscosimeter at 30 rpm.

Also, the infant formula of the invention preferably has a pH in the range of 4.0 to 7.5.

Furthermore, according to one specific embodiment of the invention, the infant formula of the invention may (also) have a low lactose content, in order to prevent and/or  
25 reduce the problems associated with (partial) lactose intolerance and/or reduced lactase activity in the colon. In this embodiment, the infant formula of the invention contains any combination of at least two, preferably at least three, and most preferably all four components A to D; and has a lactose content of at most 6,0 g/100 ml, preferably less than 4,5 g/100 ml, more preferably less than 3,0 g/100 ml of the total formula, as determined by  
30 an assay for lactose content known per se.

Such a formula may be of importance for infants that are lactose intolerant and/or that are suspected to be lactose intolerant, e.g. because they are premature and/or because they (may) have a low lactase activity, e.g. due to hereditary factors.

The infant formula of the invention may generally be prepared by mixing/combining

WO 01/41581

10

PCT/NL00/00913

the different components/ingredients in the amounts mentioned herein. This may generally be carried out in a manner known per se using well known mixing and/or processing equipment. The infant formula may also be heated/sterilised (e.g. by UHT-treatment) and is then preferably brought into a powder form, e.g. by evaporation or (spray-)drying; and  
5 aseptically packaged, e.g. in a suitable container such as a tin, a box, a bag, a flask or a sachet. A preferred method for preparing the infant formula of the invention, starting from the preferred hydrolysates used in the invention, will be discussed in more detail below.

The components A to D and any further components to be used in the invention will now be further discussed below. In this respect, it will be clear to the skilled person that any  
10 component or ingredient used in the infant formula of the invention should be acceptable for use in food products, and in particular be acceptable for use in infant formulas. Also, any component(s) or ingredients used should preferably be compatible with the other components/ingredients of the final formula, and more preferably should also not detract (too much) from the desired properties of the final formula, including but not limited to  
15 those provided by any of the other components/ingredients.

*I: Component A:*

Component A comprises intact proteins, a protein hydrolysate, or a combination thereof.

20 Component A is preferably such that it has a low phosphorus content and is preferably also such that it is easily digestible. Also, preferably, this protein source provides all amino acids that are required for optimal growth, and in sufficient amounts. Suitable sources include specific fragments of proteins from mammal milk or low-phosphorus protein from plant origin such as soy. Most preferably, for infants that could be intolerant to  
25 intact proteins, the proteins must be hydrolysed.

Preferably, this is a hydrolysate obtained by the hydrolysis of one or more milk proteins, in particular from cow's milk, including but not limited to proteins, protein fractions and/or protein preparations derived from whole milk, skimmed milk, casein and/or whey.

30 In principle, any milk protein hydrolysate known per se that is suitable for use in food products, more in particular that is suitable for use in infant formula, may be used; and such protein hydrolysates are well known in the art.

Preferably, the protein hydrolysate used has one or more, and preferably all, of the characteristics a) to e) described below. In this respect, although it is not excluded that some

WO 01/41581

11

PCT/NL00/00913

prior art methods may afford a protein hydrolysate that has one or more of the desired characteristics a) to e) - and such hydrolysates may be used in the infant formula of the invention - the present invention also provides a range of preferred protein hydrolysates, as well as a method for preparing such hydrolysates, which simultaneously show all desired characteristics a) - e). The use of these hydrolysates is particularly preferred.

In particular, a protein hydrolysate used in the invention should have one or more of the following characteristics:

a) the hydrolysate should contain all amino acids necessary for good growth of the infant;

b) at least 50% by weight of the peptides present in the hydrolysate (based upon all protein components present in the mixture, including any free amino acids) should have a chain length of between 2 and 30 amino acids, preferably of between 2 and 15 amino acids, and more preferably of between 3 and 12 amino acids; the remainder being either protein components with more amino acids in the protein chain, and/or free amino acids. Preferably, of these remaining protein components, between 0.5 to 8%, more preferably between 0.7 to 7%, and even more preferably between 0.75 and 5%, will have a chain length of more than 30 amino acids. The presence of small oligopeptides improves the digestibility of the proteins, and thereby of the entire formula. Also, the presence of oligopeptides of between 15 and 30 amino acids will allow the digestive system of the infant to get used to larger and/or intact peptides;

c) a low osmolality, due to a low content of free amino acids and salts. This prevents disturbances of the gastrointestinal tract/digestive system such as diarrhoea, or at least (further) reduces the risk thereof and prevents a low rate of emptying of the stomach. In this respect, it should be noted that, as the infant formula of the invention is in particular intended for infants that have problems adapting to food/infant formula - e.g. that suffer from one or more of the problems mentioned above - it is important that the present formulas may have a high protein content, if desired. This makes controlling the osmolality of the hydrolysate used in preparing the infant formula of the invention all the more important.

Also, as mentioned above, a low content of free amino acids is of importance as such free amino acids may provide the hydrolysate - and thereby the entire formula - with a bitter taste. For masking this bitter taste, sweeteners would need to be added to the formula, in particular sweeteners containing many free sugars such as a glucose syrup or certain hydrolysates of starch (e.g. of maize or pea ) These, however, generally have a high osmolality (such as starch hydrolysates having a DE value of > 35), which in turn would

increase (too much) the osmolality of the final formula.

Thus, it is another object of the invention to provide a protein hydrolysate-based infant formula that can contain less sweeteners and/or sweeteners with a low osmolality (e.g. with a DE value of less than 30). Preferably, as mentioned above, the osmolality of the hydrolysate is such that - when the hydrolysate is incorporated in the infant formula in the amounts indicated herein - the osmolality of the final formula is less than 270 mOsmol/l, preferably less than 240 mOsmol/l, most preferably less than 230 mOsmol/l;

d) a good taste, and in particular a taste that is not bitter, which is an extremely important characteristic for (protein hydrolysates for use in) infant formulas.

The taste, and in particular the bitterness, of a protein hydrolysate may for instance be determined in a comparative test involving a taste panel and the use of a suitable compound such as caffeine or a standard hydrolysate as a reference.

In particular, in the taste panel test described in Example 2 of US-A-5,837,312 using a 5% solution of the compound to be tested and using caffeine as the reference, any hydrolysate to be used in the infant formula of the invention should preferably have a bitter taste of less than 2.7; preferably less than 2.4, most preferably between 1.6 and 2.3 (on a scale from 1 to 6 with 6 being the value for the reference caffeine).

As is known in the art, the bitter taste of protein hydrolysates is (at least in part) due to the presence of free amino acids that are formed during hydrolysis, such as free phenylalanine and/or tyrosine). Thus, in the hydrolysates to be used in the invention, the amount of such free amino acids should be as low as possible, i.e. no more than 10 wt.%, and preferably no more than 7 wt.% of all protein components (including the free amino acids).

e) a rate of low sensibilisation, for instance as determined by the tests described by J.J. Pahud and K. Swartz in *Proc. of the Tropical Conference, Virginia 1985*, AOAC, 264-271; and/or Piacentini et al., *Allergy* 1994, 48, 361-364 or any other suitable test. In particular, the hydrolysate is such that - when the hydrolysate is incorporated in the infant formula in the amounts indicated herein - the final infant formula of the invention preferably shows a degree of sensibilisation in the tests described by Pahud and Swartz or by Piacentini, of essentially zero.

As is known in the art, the allergenic properties of a hydrolysate - and thereby of the infant formula in which it is incorporated - is for a large part dependant upon the kinds and amounts of peptides that are formed during/that remain after hydrolysis. In this respect, the use of a protein hydrolysate prepared as described below is particularly

WO 01/41581

13

PCT/NL00/00913

advantageous.

Although imbalances in the osmolality of the protein hydrolysate can be corrected by removal of ions via techniques that are known in the art, it is highly desirable that hydrolysates fulfil all characteristics a) to e) mentioned above. Such a hydrolysate can be prepared in a reliable manner via the method described below. Preferably, the hydrolysate is present in the infant formula of the invention in an amount between 1 and 3 g/100 ml, more preferably between 1.3 and 2.0 g/100 ml, and most preferably between 1.6 and 1.9 g/100 ml of the total formula.

*II: Method for preparing the preferred protein hydrolysates suitable for use as component A in the invention, and use of said hydrolysate in preparing the infant formula of the invention:*

As mentioned above, this method as well as the hydrolysates obtained by it form separate aspects of the invention.

As the starting material for the hydrolysis of the invention, any protein, mixture of proteins or protein preparation that has a phosphorus content of less than 0.75 g/100 g protein can be used. The use of proteins from mammal milk, in particular bovine milk such as whey, in particular acid whey; dephosphorylised casein;  $\beta$ -casein or a suitable mixture thereof is particularly preferred.

Most preferably, the protein starting material has a phosphorus content of less than 0.72 g P/100g protein, most preferably less than 0.69 g P/100g protein. Again, these starting materials will include whey, in particular acid whey; dephosphorylised casein; or specific casein fractions with reduced  $\alpha$ -casein content and/or increased  $\beta$ -casein content.

Optionally, the starting material may be treated to remove any (remaining) native enzymatic activity.

Also, optionally, a suspension of yeast cells, optionally homogenised and heated and/or pre-treated to crush the cell walls, may be added to the starting material prior to use in the hydrolysis of the invention, e.g. in an amount of 1-8 g dry mass of yeast cells per 100 g protein. For instance, a mixture of acid whey containing 4 % yeast protein (for instance added as a suspension of 10% baker's yeast) may be used.

The starting material - as such or in a suitable form such as a solution or suspension - is then treated with a combination of at least one endo- and at least one exoproteinase, in which said enzyme mixture is added in an amount of 0.1-5 %, based on the starting material.

The endo- and exoproteinases can be used sequentially - e.g. in two or more separate hydrolysis steps - or simultaneously, e.g. as a suitable mixture in a single hydrolysis step, optionally in combination with one or more further hydrolysis steps using any remaining enzymes. Preferably, the hydrolysis comprises a single hydrolysis step using a combination  
5 of all enzymes to be used.

Preferably, as the endo- and exoproteinases, a suitable mixture of serine proteases is used, including but not limited to a suitable enzyme mixture containing (at least) the enzymes Alcalase® and Trypsine® (both available from Novo Nordisk). Another enzyme  
10 suitable for use in said enzyme mixture is Flavourzyme® (also available from Novo Nordisk). Particularly preferred is the use of a mixture of Alcalase, Flavourzyme and Trypsine in relative amounts of about 5-10 parts Alcalase to 3-5 parts Flavourzyme to 1 part Trypsine (such as for instance a 7,5 : 4 : 1 mixture), which mixture is most preferably used in an amount corresponding to at least 0.1% - e.g. about 0.2% - Trypsine per 100 g of starting protein.

15 By using such a preferred mixture in the manner described below, a hydrolysate can be obtained that, despite the presence of relatively high molecular weight peptides/proteins, is non-sensibilising. Applying the conditions as described above allows the preparation of an infant formula of a not-bitter taste and a low osmolality (e.g. as described above).

Using a mixture of endo- and exoproteinases - and in particular of the preferred  
20 mixture of Alcalase, Flavourzyme and Trypsine - the starting material is hydrolysed at a temperature of about 45-60 °C, preferably between 50 and 58 °C, for less than 4 hours, preferably from 1.5 to 3 hours. During the hydrolysis, the pH is kept in the range of 6.4 to 8, and preferably kept essentially constant, e.g. in the range of 6.8 to 7.8.

Generally, the degree of hydrolysis is not critical. In other words, independent upon  
25 the final degree of hydrolysis, hydrolysis of the above starting materials using the enzyme combination(s) under the aforementioned conditions and for the above period of time will generally result in a hydrolysate having the desired properties for use in the infant formula of the invention. Optionally, if necessary, the skilled person will be able - on the basis of the disclosure herein - to adapt the above hydrolysis conditions such that a hydrolysate with the  
30 desired properties is obtained.

Also, it should be noted that generally - and apart from the use of the above starting materials and preferred enzyme combination(s) - the hydrolysis conditions may not be too critical, dependant upon the manner in which the hydrolysate is (further) processed prior to use in the infant formula of the invention. However, it has been found that the desired

characteristics a) to e) of the final infant formula are best and most reliably obtained when the above conditions are used in combination with the cooling step that will now be described.

5 The hydrolysis reaction may be terminated in any suitable manner. However, in order to ensure the combination of desired characteristics a) to e) in the final hydrolysate, it is most preferred that the hydrolysis reaction is not terminated/quenched by heating (as is usual), but instead by cooling the hydrolysis mixture, e.g. without specifically removing or denaturing the enzymatic activities present in the mixture.

10 In particular, according to the invention, the total reaction mixture is cooled within one hour from the hydrolysis temperature - e.g. about 45-60 °C, preferably between 50 and 58 °C - to a temperature of less than 20 °C, preferably less than 10 °C. Said cooling is preferably started between 1.5 to 3 hours after initiation of the hydrolysis reaction.

Thus, a suitable temperature protocol for the hydrolysis may be as follows:

- 15 - hydrolysis ( 45-60 °C, pref. 50-58 °C): 1.5 to 4 hours
- cooling (to <20 °C, pref. <10 °C): 10 min. to 1 hour
- total time: 1.7 to 4.5 hours

with the preferred temperature protocol for the hydrolysis being as follows:

- hydrolysis ( 45-60 °C, pref. 50-58 °C): 2.0 to 3.0 hours
- cooling (to <20 °C, pref. <10 °C): 10 minutes to 1 hour
- 20 - total time: 2.2 to 3.5 hours.

The cooled hydrolysate thus obtained may then be used as such in the preparation of the infant formula of the invention, or after suitable processing, such as removing one or more undesired compounds or components, including but not limited to salts, amino acids, 25 the enzymes used in the hydrolysis.

This may for instance be carried out by desalting (e.g. by dialysis); by precipitation, i.e. through acidification with a food grade acid such as hydrochloric acid to a pH < 5,0, followed by removing of the precipitate (e.g. by centrifugation) and re-adjusting the pH to a suitable value, for example between 6 and 7; or by any other suitable technique.

30 Also, instead of the entire hydrolysate, only a fraction thereof may be used, for instance obtained by removing (part of) the proteins with a chain length of more than 30 amino acids.

The hydrolysate thus obtained is then incorporated into the infant formula of the invention, e.g. by the following non-limiting processing steps, which are preferably carried



out within 24 hours, more preferably within 8 hours, of the end of the hydrolysis reaction:

a) All further ingredients of the final formula - e.g. the lipid component(s) B; the prebiotic component(s) C (if any); optionally a part of the viscosity improver(s) D (if any); and the optional further components, such as the vitamins, minerals and trace elements - are added to the hydrolysate.

The mixture is then homogenised and heated, in order to obtain the desired microbiological quality of the product, without detracting (too much) from the desired characteristics of the formula and/or the desired biological activity of the components incorporated therein. For instance, a UHT treatment at 140 °C during about 2.4 seconds may be used. The product is then brought into a powder form - e.g. by evaporation and (spray-)drying. It is preferred that some of the ingredients such as the viscosity improving agents D - if present - are added to the powder after spray-drying. Then, the final composition can be aseptically packaged, e.g. in a suitable container such as a tin, a box, a bag, a flask or a sachet.

b) Alternatively, after adding the water-soluble components to be incorporated into the final formula - such as the vitamins, minerals and trace elements - the hydrolysate may be heated and partially dried/evaporated, upon which the lipid component(s) B and any remaining components are added. The mixture may then be homogenised and brought into powder form. After optionally adding further powdered ingredients such as viscosity-improving agents, the final composition is packaged, i.e. as described above.

An infant formula prepared in this manner - i.e. via the aforementioned method starting from the preferred hydrolysate - has optimum characteristics with respect to taste, low osmolality, low content of free amino acids, reduced sensibilising characteristics, and a protein/amino acid content that is particularly suited for infant formula.

Also, in the method described above, the hydrolysate is subjected to only a minimal heat treatment, which ensures that the biological activity of the components present in the formula is maintained, or at least not significantly detracted.

Furthermore, the above method reliably leads to a hydrolysate and/or infant formula with the desired characteristics, which is safe and is cost-efficiently produced (limited use of expensive enzymes such as Trypsin and low production costs).

Thus, in further aspects, the invention relates to a hydrolysate obtained via the method described in this Section II; to an infant formula comprising such a protein hydrolysate; and to the use of such a protein hydrolysate in the preparation of an infant formula, in particular to the use as component A in the preparation of an infant formula of

WO 01/41581

17

PCT/NL00/00913

the invention.

As above, the preferred hydrolysate is preferably present in the infant formula of the invention in an amount between 1 and 3 g/100 ml, more preferably between 1.3 and 2.0 g/100 ml, and most preferably between 1.6 and 1.9 g/ 100 ml of the total formula.

5 However, besides their use in the invention, it is envisaged that the method described in this Section II - as well as the hydrolysates obtained via said method - may find other applications, in particular in the field of food products, more in particular in the fields of infant foods and/or dietary foods, e.g. for the prevention or treatment of food allergies, and the manufacture of foods that are intended to rapidly pass the stomach and are easily  
10 digested. The latter products can be very useful for patients suffering from an impaired stomach function, an impaired liver function, an impaired pancreas function and/or an impaired gut function.

Thus, as already mentioned, the method of this Section II as well as the hydrolysates obtained by it, form independent and separate aspects of the present invention.

15 *III: Component B:*

The at least one lipid component B - i.e. the one or more fats and/or fatty acid component(s) present in the infant formula of the invention - may be chosen from all fatty acid triglycerides known per se for use in food products, and are preferably chosen from all  
20 the fatty acid triglycerides and/or phospholipids (and/or mixtures thereof) known per se for use in infant foods, and in particular from those known per se for use in infant formulas.

As is known from the art, such fatty acid triglycerides generally comprise a glyceride molecule to which are attached, via ester bonds, three fatty acid residues, which may be the same or different, and which are generally chosen from saturated and unsaturated fatty acids  
25 containing 6 to 26 carbon atoms, including but not limited to linoleic acid,  $\alpha$ -linolenic acid, oleic acid, palmitic acid ( $C_{16}$ ) and/or stearic acid ( $C_{18}$ ).

Such fatty acid triglycerides may differ in the fatty acid residues that are present and/or in the respective position(s) of the fatty acid residues (e.g. in the 1-, 2- and/or 3- position). Usually, as is known in the art, a lipid component for use in infant formula will  
30 comprise a suitable mixture of two or more, and usually a several, different fatty acid triglycerides, depending upon for instance the desired properties of the lipid component, the source of the fat, as well as the way in which the fat was obtained.

The at least one lipid component B - i.e. the one or more fatty acid triglycerides present therein - are preferably chosen such that the lipid component B is easily digestible

WO 01/41581

18

PCT/NL00/00913

by the infant, thereby (also) making the final formula easily digestible. This improves the structure of the faeces and improves the biological availability of divalent cations such as calcium and/or the fats/fatty acids present in the formula.

In this respect, the amount and position of the palmitic acid residues that are present in the triglycerides that are present in/make up the at least one lipid component B are of special significance. Preferably, palmitic acid residues should make up more than 10 %, preferably 16 - 24 %, of all fatty acid residues present in the triglycerides used as or in component B.

Also, the amount of triglycerides in which the C<sub>14:0</sub>, C<sub>16:0</sub> and/or C<sub>18:0</sub> fatty acids are in the Sn1- or Sn3-position and in particular in which the palmitate residues are in the Sn1 or Sn3-position should be as low as possible. The amount of palmitic acid in the Sn1 or Sn3-position should preferably make up no more than 16 %, more preferably no more than 13 %, and most preferably no more 10.7 %, of all triglycerides present. This corresponds to amounts of triglycerides with the palmitate residue in the Sn1- or Sn3-position of less than 0.55 g/100 ml, preferably less than 0.50 g/100 ml, most preferably less than 0.38 g/100 ml of the infant formula of the invention.

In other - but somewhat less restrictive - words, when the palmitic acid residues make up more than 10%, preferably 16 - 24 % of all fatty acid residues present in the triglycerides used in or as component B of the invention, of these palmitic acid residues, as much as possible, and preferably at least 30%, more preferably at least 40 %, should be in the 2- or  $\beta$ -position of the triglyceride.

Mixtures of fatty acid triglycerides that contain more than 10 %, preferably 16 - 24 % palmitate residues and that meet one or both of the requirements relating to the position of the palmitate residues set out in the above two paragraphs, will also be referred to below as the "*preferred lipid component B*". For instance, these include specific phospholipids as well as so-called structured fats, e.g. fats of animal or plant origin, in which the triglycerides have been subjected to enzymatic or other re-esterification such that the palmitic acid residues are for a large part present in the 2-position.

Such preferred components B are commercially available - e.g. from Lodders Croklaan under the name Betapol® (beta palmitate) - and/or can be prepared in a manner known per se., for instance as described in EP 0 698 078 and/or EP 0 758 846.

However, because of the better absorption of these fat mixtures from the infant gut, the use of a preferred lipid component B as described above may allow the amount of component B that is added to the infant formula of the invention to be reduced, while still

providing sufficient energy/nutritional value to the infant.

In particular, by using a preferred lipid component B, the overall fat content of the infant formula of the invention may be reduced from 48 wt.% or more for conventional infant formulas to less than 46 wt.% in an infant formula of the invention.

5 Also, the use of a preferred lipid component B may allow the overall calcium content of the infant formula of the invention to be lowered, i.e. as set out above. Such a reduction in the calcium content may in turn allow the overall phosphorus content of the infant formula of the invention to be lowered, again as set out above.

10 Alternatively, the use of a preferred lipid component B may allow the calcium-to-phosphorus ratio of the infant formula of the invention to be lowered, e.g. from about 2 for conventional formulas to a range of about 2.0 to 1.4.

15 Finally, although component B has been described above as essentially only consisting of fatty acid triglycerides, it should be understood that the presence of minor amounts of mono- or diglycerides (e.g. to a total of at most one-third of all fatty acids of all fatty acid mono-, di- and triglycerides present in or as component B, the remainder being fatty acid triglycerides to a total of 100% of component B) is not excluded. Such mono- or diglycerides will usually contain the fatty acid residues referred to above.

#### *IV: Component C:*

20 The one or more prebiotic components C may be chosen from all prebiotic components known per se for use in food products, and are preferably chosen from the prebiotic components known per se for use in infant foods, and in particular from those known per se for use in infant formulas.

25 Some preferred but non-limiting examples thereof include prebiotic (non-digestible) oligosaccharides. Generally, these will be hydrolysed or non-hydrolysed carbohydrates comprising sugar residues interconnected via *beta* 1-1, 1-2, 1-3, 1-4, 1-6 and/or *alpha* 1-6 linkages. Most preferably, such oligosaccharides will contain 2-20 sugar residues in the saccharide backbone.

30 For instance, such prebiotic oligosaccharides include, but are not limited to, lacto-N-tetraose, lacto-N-fucopentaose, lactulose, lactosucrose, raffinose, galacto-oligosaccharides, fructo-oligosaccharides, oligosaccharides derived from soybean polysaccharides, mannose-based oligosaccharides, arabino-oligosaccharides, xylo-oligosaccharides, isomalto-oligosaccharides, glucans, sialyl oligosaccharides, fuco-oligosaccharides, and/or any suitable combination thereof.

WO 01/41581

20

PCT/NL00/00913

Also, lactose may be used as the prebiotic. However, the use of lactose in the infant formula of the invention should be avoided when a formula with low lactose content is desired, e.g. a formula for infants that are, or are suspected to be, lactose intolerant (e.g. based on age or hereditary factors) .

5       The use of one or more *trans*-galacto-oligosaccharides ("*TOS*"), one or more fructo-oligosaccharides ("*FOS*") and/or mixtures thereof is particularly preferred, in particular the use of mixtures of one or more *trans*-galacto-oligosaccharides and one or more fructo-oligosaccharides in which the ratio of TOS-to-FOS is between 5:1 and 15:1, and more in particular about 9:1, which mixtures generally provide a prebiotic effect comparable to  
10       mothers milk.

      The amount of the one or more prebiotic components C used will generally depend upon the specific prebiotic component(s) used, as well as on the amount of formula to be fed to the infant per day, e.g. as one or more, and preferably four or more, feedings per day. Generally, the amount of prebiotic component(s) C will be such that - when the formula is  
15       fed to the infant in the amount recommended/prescribed - it is sufficient to provide a daily dose of prebiotic component(s) of at least 1.8 g/day for infants of less than 4 months old; and preferably at least 3.6 g/day for infants of more than 4 months old. Normally, an infant will be fed a total of between 500 and 800 ml of the formula of the invention per day. Thus, the above amounts correspond to an amount of component(s) C at least 0.3 g/100 ml of the  
20       total formula, more preferably at least 0.6 g/100 ml of the total formula.

      The use of the above prebiotics in the infant formula of the invention may (help to) restore the natural gastrointestinal flora and/or will result in a reduction of aggressive components in the faeces, e.g. of components that may irritate or harm epithelial cells (such as those of the lining of the gastrointestinal tract and/or the skin). The latter is of extreme  
25       importance for infants suffering from diaper rash.

*V: Component D:*

      The one or more viscosity improving components D may be chosen from all viscosity improving components known per se for use in food products, and are preferably  
30       chosen from the viscosity improving components known for use in infant foods, especially from those known per se for use in for infant formulas; see for example EP 0 846 422..

      Some preferred but non-limiting examples thereof include viscosity improving components based upon carbohydrates, and in particular those based upon starches and/or starch derivatives such as pregelatinised starches, such as pregelatinised potato starch,

WO 01/41581

21

PCT/NL00/00913

which is preferred.

The amount of the one or more viscosity improving component(s) D used will generally depend upon the specific viscosity improving component(s) used and on the other components present in the formula, and will generally be such that the viscosity of the final formula is between 20 and 100 cps, preferably between 40 and 80 cps; as measured in a Brookfield viscosimeter at 30 rpm. Usually, the total amount of viscosity improving component(s) D will be between 0.5 and 5 g/100 ml of the formula, preferably between 1 and 3 g/100 ml. For instance, pregelatinised potato starch may be used in an amount of between 1.4 and 2.1 g/100ml.

The use of the viscosity improving component(s) D may provide several advantages, including but not limited to prevention or reduction of regurgitation and/or excessive aerophagia (burps).

*VI: Further components:*

Besides the above-mentioned components A to D, the composition of the invention may further contain any component or ingredient for infant formula known per se, in usual amounts (e.g. as prescribed by national or international guidelines) and depending upon (the properties of) the final formula desired. Such further components may include, but are not limited to, one or any combination of the following:

- one or more of the following compounds: taurine, choline, carnitine, inositol, biotin;
- one or more polyunsaturated long chain fatty acids ("PUFAs"), including but not limited to linoleic acid,  $\alpha$ -linolenic acid, oleic acid, arachidonic acid and docosahexaenoic acid.
- one or more nucleotides and/or nucleotide analogues;
- one or more (added) amino acids, including but not limited to tryptophan and/or methionine;
- one or more (added) vitamins, including but not limited to vitamin K, vitamin B1, vitamin B2, vitamin A, vitamin E, vitamin D, vitamin C, niacin, pantothenic acid. Also, besides the usual amounts of these or other vitamins, the infant formula of the invention may contain additional amounts of - for instance - folic acid, vitamin B12 and/or vitamin B6;
- one or more minerals and/or trace elements;
- one or more preservatives (not preferred);
- one or more flavours and/or colourings.

**Examples:****Example 1: Formula for infants of more than 4 months old.**

An infant formula for infants of more than 4 months old is prepared essentially as described under II. above. The formula has the following composition, an energy/nutritional  
 5 value of 72 kcal/ml and an osmolality of 260 mOsmol/l. The calcium content is 86 mg/100 kcal and the phosphorus content is 54 mg/100kcal.

	<u>Component</u>	<u>g per 100 g powder</u>	<u>g per 100 ml*</u>
10	Protein equivalents	12.4	1.9
	Whey-protein hydrolysate**		1.9
	Carbohydrates	54.8	8.6
	Saccharides (lactose)		4.0 (2.7)
15	Polysaccharides from maltodextrins		2.0
	Polysaccharides from potato starch		2.3
	Organic acids		0.1
	Fat	21.1	3.3 (= 41 wt.%)
20	Saturated		1.4
	Beta palmitate (Loders Croklaan)		0.23
	Mono-unsaturated		1.4
	Poly-unsaturated		0.54
25	Fibre / non-digestible oligosaccharides	5.0	0.78
	TOS		0.7
	FOS		0.08
30	Further components:		
	Minerals, trace elements and vitamins		
	in amounts as recommended by the EEC regulation 321.		

Notes: \*: obtained by dissolving 15.6 g powder in 100 ml water.

\*\* : preferred protein hydrolysate A as described under II. above.

**Example 2: Formula for infants of up to 6 months old.**

An infant formula for infants of up to 6 months old is prepared essentially as described under II. above. The formula has the following composition, an energy/nutritional value of 70 kcal/ml and an osmolality of 240 mOsmol/l. The calcium content is 53 mg/100

5 kcal and the phosphorus content is 27 mg/100kcal.

<u>Component</u>	<u>g per 100 g powder</u>	<u>g per 100 ml*</u>
Protein equivalents	11.6	1.7
10 Whey-protein hydrolysate**		1.7
Carbohydrates	55.4	8.3
Saccharides (lactose)		4.0 (2.9)
Polysaccharides from maltodextrins		1.5
15 Polysaccharides from potato starch		1.8
Fat	21.1	3.3 (= 42 wt.%)
Saturated		1.4
Beta palmitate		0.23
20 Mono-unsaturated		1.4
Poly-unsaturated		0.54
Fibre / non-digestible oligosaccharides	5.0	0.78
TOS		0.7
25 FOS		0.08
Further components:		
Minerals, trace elements and vitamins		
in amounts as recommended by the EEC regulation 321.		

30

Notes: \*: obtained by dissolving 15.0 g powder in 100 ml water.

\*\* preferred protein hydrolysate A as described under II. above.



Example 3: Formula for infants of up to 4 months old.

An infant formula for infants of up to 4 months old is prepared essentially as described under II. above. The formula has the following composition, an energy/nutritional value of 67 kcal/ml and an osmolality of 230 mOsmol/l. The calcium content is 45 mg/100 kcal and the phosphorus content is 25 mg/100kcal.

	<u>Component</u>	<u>g per 100 g powder</u>	<u>g per 100 ml*</u>
	Protein equivalents	10.5	1.54
10	Hydrolysed whey**		1.46
	From L-tryptophan		0.01
	From L-methionine		0.01
	From hydrolysed baker's yeast**		0.06
15	Carbohydrates	55.4	8.3
	Saccharides (lactose)		3.5
	Polysaccharides from maltodextrins		3.3
	Polysaccharides from potato starch		1.4
20	Fat	19.2	3.0 (= 40 wt.%)
	Saturated		1.2
	Beta palmitate		0.23
	Mono-unsaturated		1.3
	Poly-unsaturated		0.5
25	Fibre / non-digestible oligosaccharides	3.2	0.5
	TOS		0.37
	FOS		0.03
	Lacto-N-tetraose		0.10
30	Further components:		
	Folic acid (µg)		20
	Vitamin K (µg)		10
35	Minerals, trace elements and vitamins: in amounts as recommended by the EEC regulation 321.		

Notes: \*: obtained by dissolving 15.0 g powder in 100 ml water.  
\*\*: preferred protein hydrolysate A as described under II. above.

WO 01/41581

25

PCT/NL00/00913

Example 4: Formula for infants of up to 4 months old.

An infant formula for infants of up to 4 months old is prepared essentially as described under II. above. The formula has the following composition, an energy/nutritional value of 68 kcal/100 ml and an osmolality of 260 mOsmol/l. The calcium content is 40 mg/100 kcal and the phosphorus content is 20 mg/100kcal.

<u>Component</u>		<u>g per 100 ml*</u>	
Protein equivalents		1.30	
10	Hydrolysed $\beta$ -casein/whey (40/60)		1.29
	From L-tryptophan		0.01
Carbohydrates		8.5	
	Lactose		5.5
15	Polysaccharides		2.8
Lipids		3.2	
	Saturated		1.5
	From $\beta$ -palmitate		0.2
20	From MCT's + coconut oil		1.1
	Mono-unsaturated		1.2
	Poly-unsaturated		0.5
Fibre / non-digestible oligosaccharides		0.5 g	
25	Arabino oligosaccharides		0.4
	FOS		0.1
Further components:			
30	Minerals, trace elements and vitamins:		
	in amounts as recommended by the EEC regulation 321.		

Notes \*: obtained by dissolving 14.5 g powder in 100 ml water.

Example 5: Comparative study

The effects of the formula of example 2 was tested in a study involving 51 term infants and were compared to the effects of a standard commercial product not containing beta palmitate and no adapted calcium to phosphorus ratio. After prolonged feeding of the formulae, significantly less problem with constipation ( $p<0.05$ ), abdominal discomfort ( $p<0.005$ ) and minor gastrointestinal problems ( $p<0.01$ ), as well as less problems associated with gastrointestinal discomfort (cramps and crying) were observed with the formula of the invention compared to the standard formula.

WO 01/41581

26

PCT/NL00/00913

## CLAIMS

1. Infant formula, comprising
  - a) at least one protein component; and
  - b) at least one lipid component that can be easily digested by an infant;the protein component a) having a phosphorus content of less than 0.75 g P/100 g protein.
2. Infant formula according to claim 1, in which the protein component a) has a phosphorus content of less than 0.72 g P/100 g protein, more preferably less than 0.69 g P/100 g protein.
3. Infant formula according to claim 1 or 2, in which the lipid component b) comprises at least one fatty acid triglyceride in which palmitic acid residues make up more than 10 % of all fatty acid residues present in the triglyceride; and in which: the triglycerides in which the palmitate residue is in the Sn1- or Sn3-position make up no more than 16 % of all triglycerides present.
4. Infant formula according to any one of claims 1-3, in which the at least one protein component a) is a hydrolysate obtained by hydrolysing a starting material comprising proteins from mammalian milk or a dephosphorylated protein from plant origin with a combination of at least one endo- and at least one exoproteinase.
5. Infant formula according to claim 4, in which the hydrolysate used as component a) is obtained by hydrolysing a starting material comprising a milk protein, a mixture of milk proteins and/or a milk protein preparation with a combination of at least one endo- and at least one exoproteinase;
6. Infant formula according to any one of claims 1-5, further comprising at least one of:
  - c) at least one prebiotic component;
  - d) at least one viscosity-improving component.

WO 01/41581

27

PCT/NL00/00913

7. Infant formula according to any one of claims 1-6, characterised by a content of free amino acids, derived from the protein hydrolysate a), of less than 10 g, and preferably less than 7 g per 100 g protein equivalent.
8. Infant formula according to any one of claims 1-7, characterised by an osmolality of less than 270 mOsmol/l, preferably less than 240 mOsmol/l.
9. Infant formula according to any one of claims 1-8, intended for infants of less than 6 months old, characterised by a calcium content (expressed as mg of calcium per 100 kcal of energy content of the formula) of less than 80 mg/100kcal.
10. Infant formula according to any of claims 1-8, intended for infants of more than 6 months old, characterised by a calcium content (expressed as mg of calcium per 100 kcal of energy content of the formula) of less than 122 mg/100kcal.
11. Infant formula according to any of claims 1-10, characterised by a calcium-to-phosphorus ratio of between 1.4 and 2.
12. Infant formula according to any of the preceding claims, characterised by an overall fat content (expressed as total lipid content) of between 20 and 45 wt.%.
13. Infant formula according to any of claims 1-12, in which the relative amounts of the components a) to d) and further components are:

– the at least one protein component a):	6.4 to 16 wt.%
– the at least one lipid component b):	18 to 29 wt.%
– at least one prebiotic component c):	0 to 15 wt.%
– at least one viscosity improving component d):	0 to 15 wt.%
– further components:	0 to 60 wt.%

to a total of 100 wt.% of the final formula.
14. Infant formula according to claim 13, in which:

the relative amount of component c) is	3.0 to 15 wt.%,
and/or the relative amount of component d) is:	1.5 to 15 wt.%.

15. Infant formula according to any of the preceding claims, characterised by a viscosity of between 20 and 100 cps, more preferably between 40 and 80 cps; as measured in a Brookfield viscosimeter at 30 rpm.
16. Infant formula according to any of the preceding claims, characterised by a lactose content of at most 6,0 g/100 ml, preferably at most 4,5 g/100ml, of the total formula.
17. A process for preparing a protein hydrolysate, comprising hydrolysing a protein starting material having a phosphorus content of less than 0.75 g P/100 g protein with a combination of at least one endo- and at least one exoproteinase.
18. A process according to claim 17, comprising hydrolysing a starting material comprising a milk protein, a mixture of milk proteins, and/or a milk protein preparation.
19. A process according to claim 18, comprising hydrolysing proteins from mammal milk, in particular from bovine milk, such as whey, in particular acid whey; dephosphorylised casein; or a suitable mixture thereof..
20. A process according to any one of claims 17-19, in which the starting material further contains a suspension of yeast cells in an amount of 1 to 8 g dry mass of yeast cells per 100 g protein.
21. A process according to any one of claims 17-20, in which the combination of the endo- and exoproteinases is a mixture containing the enzymes Alcalase®, Trypsine® and Flavourzyme®.
22. A process according to any one of claims 17-21, in which the hydrolysis is carried out at a temperature between 45 and 60 °C, and is terminated by cooling the total hydrolysis mixture from the hydrolysis temperature to a temperature of less than 20 °C, preferably less than 10 °C, over a period of time of 10 min. to 1 hour.
23. A protein hydrolysate obtained by the process of any one of claims 17-22.
24. Infant formula, comprising a protein hydrolysate of claim 23.

25. Infant formula according to claim 23, further comprising
- b) at least one lipid component that can be easily digested by an infant;  
and optionally one or two of:
  - c) at least one prebiotic component;
  - d) at least one viscosity improving component.
26. Use of a protein hydrolysate of claim 23 in the preparation of an infant formula, in particular an infant formula of one of claims 1-16.

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/NL 00/00913

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 A23D9/00 A23L1/305 A23J3/34

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 A23D A23L A23J

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)  
EPO-Internal, WPI Data, PAJ, FSTA, BIOSIS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 658 714 A (SCHIMPF KAREN JOYCE ET AL) 19 August 1997 (1997-08-19) column 10, line 54 -column 11, line 24	1,2,6,12
Y		3-5, 7-11,13, 16,25
Y	EP 0 376 628 A (AMERICAN HOME PROD) 4 July 1990 (1990-07-04) page 5, line 39-49 page 6, line 50,51 page 7, line 2-4 example 1 claim 1	3,9-11, 13,16
A		14

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*G\* document member of the same patent family

Date of the actual completion of the international search

20 March 2001

Date of mailing of the international search report

27/03/2001

Name and mailing address of the ISA  
European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Rooney, K

INTERNATIONAL SEARCH REPORT

In International Application No  
PCT/NL 00/00913

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5 486 461 A (NIELSEN PER M) 23 January 1996 (1996-01-23) column 5, line 52,53 claim 1 ----	4,5,7
Y	EP 0 846 422 A (SQUIBB BRISTOL MYERS CO) 10 June 1998 (1998-06-10) cited in the application page 4, line 30,31 page 3, line 30 ----	8
A		15
X	EP 0 671 126 A (MORINAGA MILK INDUSTRY CO LTD) 13 September 1995 (1995-09-13) page 3, line 21 page 8, line 48-56 claims 1,5; example 4 ----	17-19, 23,24,26
Y		21,25
A		20,22
Y	US 5 994 113 A (KAUPPINEN MARKUS SAKARI ET AL) 30 November 1999 (1999-11-30) column 1, line 34-40 column 9, line 2-12 ----	21
A	MULLALLY, M.M, O'CALLAGHAN, D. M., FITZGERALD, R. J., DONNELLY, W. J., AND DALTON, J. P.: "Proteolytic and Peptidolytic Activities in Commercial Pancreatic Protease Preparations and Their Relationship to Some Whey Protein Hydrolysate Characteristics." JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, vol. 42, 1994, pages 2973-2981, XP002137344 page 2973, column 1, paragraph 1 table 1 -----	17,18



## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/NL 00/00913

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5658714 A	19-08-1997	CA 2060973 A DE 69207228 D DE 69207228 T EP 0501117 A IE 914558 A US 5270450 A	29-08-1992 15-02-1996 04-07-1996 02-09-1992 09-09-1992 14-12-1993
EP 0376628 A	04-07-1990	US 5000975 A AT 103772 T AU 627532 B AU 4732189 A CA 2006136 A,C DE 68914426 D DE 68914426 T DK 670289 A EG 18568 A ES 2050824 T FI 97682 B GB 2226569 A,B HK 25294 A HU 55611 A HU 9500482 A IE 64314 B IL 92809 A JP 2231037 A JP 3021499 B KR 133280 B MX 165950 B NZ 231919 A PH 27306 A PT 92681 A,B SG 26694 G TR 25188 A ZA 8909975 A	19-03-1991 15-04-1994 27-08-1992 05-07-1990 29-06-1990 11-05-1994 06-10-1994 30-06-1990 30-08-1993 01-06-1994 31-10-1996 04-07-1990 31-03-1994 28-06-1991 28-09-1995 26-07-1995 08-07-1993 13-09-1990 15-03-2000 14-04-1998 10-12-1992 28-04-1992 28-05-1993 29-06-1990 10-06-1994 01-01-1993 28-08-1991
US 5486461 A	23-01-1996	AT 142430 T AU 657451 B AU 2942392 A CA 2123091 A DE 69213755 D DE 69213755 T WO 9308702 A DK 610411 T EP 0610411 A FI 942122 A JP 7500733 T JP 3121014 B KR 259127 B NO 941701 A NZ 245031 A RU 2086143 C	15-09-1996 09-03-1995 07-06-1993 13-05-1993 17-10-1996 06-02-1997 13-05-1993 23-12-1996 17-08-1994 06-05-1994 26-01-1995 25-12-2000 15-06-2000 06-05-1994 26-01-1994 10-08-1997
EP 0846422 A	10-06-1998	AT 171846 T BR 9602558 A CA 2177229 A CZ 9601497 A DE 69600745 D DE 69600745 T	15-10-1998 22-04-1998 02-12-1996 11-12-1996 12-11-1998 06-05-1999

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

International Application No  
**PCT/NL 00/00913**

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0846422 A		DE 745330 T	15-05-1997
		DK 745330 T	15-02-1999
		EP 0745330 A	04-12-1996
		ES 2094716 T	01-02-1997
		GR 97300004 T	28-02-1997
		PL 314546 A	09-12-1996
		US 6099871 A	08-08-2000
EP 0671126 A	13-09-1995	AU 682479 B	09-10-1997
		AU 5575094 A	22-06-1994
		DE 69329923 D	15-03-2001
		US 5744179 A	28-04-1998
		CA 2150571 A,C	09-06-1994
		WO 9412053 A	09-06-1994
		NZ 258207 A	27-02-1996
US 5994113 A	30-11-1999	AU 4939396 A	02-10-1996
		WO 9628542 A	19-09-1996
		EP 0815210 A	07-01-1998
		JP 11509082 T	17-08-1999
		US 6143546 A	07-11-2000